The latest updates on ensifentrine-Ohtuvayre’s domestic application for marketing in 2026

Ensifentine Inhalation Suspension Solution (Ensifentrine), trade nameOhtuvayre, is a new type of respiratory drug, mainly used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) . The drug dilates bronchial tubes and relieves lung inflammation by inhibiting PDE3 and PDE4 enzymes. However, exefantine is not currently available in the Chinese market. Although there is news that some administrative regions may obtain the drug, the overall market price, medical insurance and other related information are still unclear.

According to the latest application information, Exefantine is applying for marketing approval from the Chinese Food and Drug Administration (NMPA) and may officially enter the Chinese market. As a highly innovative drug, the launch of exefantine has brought new treatment options to Chinese COPD patients, especially when the existing treatment options are unsatisfactory. Exefantine can significantly improve respiratory symptoms and reduce lung inflammation through its unique dual mechanism of action, which simultaneously inhibits PDE3 and PDE4 enzymes. Although it is currently unclear the specific price of the drug and whether it will be included in medical insurance, as the market advances, it is expected that more price information and medical insurance coverage details will be announced in the future.

ForCOPD patients, the launch of exefantine will undoubtedly add more treatment options, especially for those patients who have poor response to existing drug treatments. As the drug gradually advances in the domestic market, relevant medical insurance and price information will gradually become transparent, allowing patients and medical institutions to better evaluate its applicability and economics.

Generally speaking, As ofJanuary 2026, exefantine has not been marketed for sale in China. If it is on the market, the arrival of exefantine has brought new hope to the treatment of chronic obstructive pulmonary disease in China.

Keyword tags: Ensifentrine, Ensifentrine, Ohtuvayre, domestic application, marketing trends, chronic obstructive pulmonary disease, COPD, drug prices, drug and medical insurance, respiratory drugs

Reference materials：https://ohtuvayre.com/